SCHEMBL135374

SCHEMBL135374

CCC(=O)Nc1c(C(=O)O)cccc1-c1ccccc1O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 1/20 0.45
HCAR2 Q8TDS4 1/20 0.44
SMN1; SMN2 Q16637 5/20 0.43
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 2/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
HMGB1 P09429 1/20 0.43
HPGD P15428 1/20 0.43
CA4 P22748 1/20 0.43
CA6 P23280 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
NAPRT Q6XQN6 1/20 0.43
CA14 Q9ULX7 1/20 0.43
PTPN11 Q06124 2/20 0.43
POLB P06746 2/20 0.42
MAPT P10636 3/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18230845 0.86 POLB (0.51) SMN1; SMN2ALDH1A1KDM4EHPGDNAPRT
SCHEMBL2965336 0.85 HNF4A (0.50) SMN1; SMN2ALDH1A1KDM4EHPGDPOLB
SCHEMBL10732738 0.79 RAB9A (0.50) SMN1; SMN2ALDH1A1CA12CA1CA2
1,5-Pentanediol SCHEMBL18191835 0.77 ALDH1A1 (0.46) SMN1; SMN2ALDH1A1KDM4EHPGDPOLB
SCHEMBL9958891 0.77 POLB (0.60) ALDH1A1KDM4EHPGDPOLBMAPT
SCHEMBL5530486 0.77 ALDH1A1 (0.50) HCAR2SMN1; SMN2ALDH1A1KDM4ECA12
SCHEMBL8773868 0.76 ALB (0.47) SMN1; SMN2ALDH1A1KDM4EPOLBMAPT
SCHEMBL4397955 0.76 PTPN11 (0.50) PLK1SMN1; SMN2ALDH1A1KDM4ECA12
SCHEMBL20853618 0.75 KCNQ2 (0.42) PLK1HCAR2SMN1; SMN2ALDH1A1KDM4E
SCHEMBL30195450 0.74 PTPN11 (0.58) PLK1SMN1; SMN2ALDH1A1KDM4ECA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 520 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743051-A1 3-HYDROXYPROPYLESTERS AS SOLUBILITY ENHANCERS FOR LIPOPHILIC INGREDIENTS Symrise AG (DE) 2026-05-20 EP claimed
US-12576018-B2 Active agents for skin and hair care with sensory modifying properties SYMRISE AG (DE) 2026-03-17 US claimed
EP-4110276-B1 COMPOSITIONS COMPRISING ALKANEDIOLS SYMRISE AG (DE) 2026-01-28 EP claimed
US-20250255833-A1 Compositions Comprising One or More (Bio)-Alkanediols with Antioxidants SYMRISE AG (DE) 2025-08-14 US claimed
EP-4565194-A1 ODOR AND COLORANT STABILIZED COMPOSITIONS Symrise AG (DE) 2025-06-11 EP claimed
US-12303468-B2 Compositions comprising one or more (bio)-alkanediols with antioxidants SYMRISE AG (DE) 2025-05-20 US claimed
EP-4545065-A2 COMPOSITIONS COMPRISING ONE OR MORE (BIO)-ALKANEDIOLS WITH ANTIOXIDANTS Symrise AG (DE) 2025-04-30 EP claimed
EP-4110477-B1 COMPOSITIONS COMPRISING ONE OR MORE (BIO)-ALKANEDIOLS WITH ANTIOXIDANTS SYMRISE AG (DE) 2025-03-19 EP claimed
WO-2025011745-A1 3-HYDROXYPROPYLESTERS AS SOLUBILITY ENHANCERS FOR LIPOPHILIC INGREDIENTS SYMRISE AG (DE) 2025-01-16 WO claimed
EP-4477264-A2 COMPOSITIONS COMPRISING ONE OR MORE (BIO)-ALKANEDIOLS WITH ACTIVE INGREDIENTS Symrise AG (DE) 2024-12-18 EP claimed
US-20160184205-A1 OXIDATIVE DYEING COMPOSITION KAO GERMANY GMBH (DE) 2016-06-30 US claimed
WO-2015180740-A1 OXIDATIVE DYEING COMPOSITION KAO GERMANY GMBH (DE) 2015-12-03 WO claimed
US-20150118334-A1 TOPICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC INFLAMMATORY SKIN DISEASE KAMEDIS LTD. (IL) 2015-04-30 US claimed
EP-2861239-A2 TOPICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC INFLAMMATORY SKIN DISEASE Kamedis Ltd. (IL) 2015-04-22 EP claimed
WO-2014041542-A2 TOPICAL COMPOSITIONS FOR THE TREATMENT OF ACNE KAMEDIS LTD (IL) 2014-03-20 WO claimed
WO-2014030155-A2 TOPICAL COMPOSITIONS FOR THE TREATMENT OF PSORIASIS AND SEBORRHEA KAMEDIS LTD (IL) 2014-02-27 WO claimed
WO-2013190548-A2 TOPICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC INFLAMMATORY SKIN DISEASE KAMEDIS LTD (IL) 2013-12-27 WO claimed
US-20120276033-A1 Temperature Management Composition KIMBERLY-CLARK WORLDWIDE, INC. 2012-11-01 US claimed
WO-2012146994-A2 TEMPERATURE MANAGEMENT COMPOSITION KIMBERLY-CLARK WORLDWIDE, INC. (US) 2012-11-01 WO claimed
EP-2494973-A1 Topical compositions for the treatment and prevention of skin diseases, in particular radiation dermatitis caused by ionising radiation Sinerga Group S.r.l. (IT) 2012-09-05 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250255833-A1 Compositions Comprising One or More (Bio)-Alkanediols with Antioxidants MMP8, CXCL8, IL18 PLK1 4848/4885HCAR2 96/4885SMN1; SMN2 3618/4885
US-20160184205-A1 OXIDATIVE DYEING COMPOSITION POR, CYP4A22, CYP3A43 PLK1 4429/4885HCAR2 1547/4885SMN1; SMN2 4655/4885
US-12303468-B2 Compositions comprising one or more (bio)-alkanediols with antioxidants MMP8, CXCL8, IL18 PLK1 4848/4885HCAR2 96/4885SMN1; SMN2 3618/4885
US-12576018-B2 Active agents for skin and hair care with sensory modifying properties SCD5, SMURF1, SGMS1 PLK1 3961/4885HCAR2 1434/4885SMN1; SMN2 3245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.